Zantac’s manufacturers were on a roll. Their defense had exacted a spate of favorable decisions and jury verdicts. Yet, on October 9, Glaxo Smith Kline (GSK) suddenly settled 93% of the remaining cases – for 2.2 billion dollars.
ACSH relies on donors like you. If you enjoy our work, please contribute.
Make your tax-deductible gift today!
Popular articles
ACSH Podcasts
Stay curious. Stay informed.
Free, independent writing delivered weekly. No ads, no sponsored fluff, and we never share or sell your data.
Join NowAlways free. Never shared.
